Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oleclumab - MedImmune

Drug Profile

Oleclumab - MedImmune

Alternative Names: Anti-CD73 MAb; Anti-CD73 monoclonal antibody; MEDI-9447

Latest Information Update: 31 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; European Network of Gynaecological Oncological Trial Groups; Jules Bordet Institute; MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
  • Phase I/II Colorectal cancer
  • Phase I Bladder cancer; Solid tumours

Most Recent Events

  • 19 Oct 2019 Medimmune plans a phase II COLUMBIA-2 trial for Microsatellite-stable colorectal Cancer (Combination therapy, adjuvant therapy, First-line therapy) in the US, Canada, France and Spain (IV)(NCT04145193)
  • 20 Sep 2019 Phase-II clinical trials in Breast cancer (Combination therapy, Neoadjuvant therapy) in Belgium (IV) (NCT03875573; EudraCT2018-004165-13)
  • 29 Aug 2019 Phase-II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04089553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top